Systematic Reviews
Copyright ©The Author(s) 2024.
World J Exp Med. Jun 20, 2024; 14(2): 94135
Published online Jun 20, 2024. doi: 10.5493/wjem.v14.i2.94135
Table 1 Ischaemia models of high-risk anastomosis
Ref.
Year
Sample size
Intervention
Test
Sampling day
Uzun et al[20]200856Sildenafil citrateNOx, thiobarbituric acid reactive substances, glutathione3/7
Karliczek et al[21]200934Visible light spectrometry evaluationBPR in situ, tensile strength3/7
Coneely et al[22]201050KetotifenBPR ex situ, HP, IL-6, VEGF4
Karataş et al[23]201024AmelogeninBPR ex situ, HP4
Kaya et al[24]201048TadalafilBPR ex situ, HP, histology (as per Ehrlich et al[25])4
Adas et al[26]201140Bm-MSCs 1 × 106BPR in situ, HP4/7
Karatepe et al[27]201140AdrenomedulinBPR ex situ, HP, spectrophotometry, MDA, NOx, TNF-a, IL-6, VEGF, histology3/7
Kennelly et al[28]201130Electrical field stimulationBPR ex situ, HP, IL-6, VEGF4
Sümer et al[29]201130Pentoxifylline and vinpocetineBPR in situ, HP, histology (as per García et al[30])5
Yoo et al[31]201260AdMSC 1 × 106BPR ex situ, weight loss, macroscopic (adhesions as per van der Ham and Kort[32], strictures, ulcers), histology (as per Phillips et al[33]), wound infection, ileus, mortality7
Wu et al[34]201324TriptolideHistology, calprotectin, MPO, INF-g, IL-4, IL-17, TGF-b56
Portilla-de Buen et al[35]2014180Fibrin glueBPR ex situ, macroscopic, microscopic, HP5
Boersema et al[36]201640Hyperbaric oxygenMacroscopic (as per Zühlke et al[37]), histology (as per Phillips et al[33]), serum creatinine3/7
Ruiz-Luque et al[38]201993AlprostadilBPR in situ, macroscopic (as per Knightly et al[39]), histology (as per García et al[30])8
Kayapinar et al[40]202160CORM-2BPR ex situ, HP, glutathione, MDA, histology (as per Ehrlich et al[25])3/7
Table 2 Colitis models of high-risk anastomosis
Ref.
Year
Colitis method
Sample size
Intervention
Test
Sampling day
Kirkil et al[41]2008Intra-jejunal injection of iodoacetamide28Endothelin receptor blockade by bosentanBPR in situ, macroscopic (Mannheim index[42]), HP, histology (as per Mei et al[43])4
Rijcken et al[44]20107 d DSS 5%Not mentionedrhIGF-1BPR in situ, microscopic (as per Phillips et al[33], Ki-67), HP, MPO1/3/7
Myrelid et al[45]20155 d DSS 3%140IP prednisolone, AZA, infliximabBPR ex situ, bowel WT/length, histology, zymography3
Alvarenga et al[46]20192,4,6-TNBS66AdMSC 2 × 106Histology, IL-10, IL-17, IFN-g, TGF-b, TNF-a, MMP-2, MMP-97
Reischl et al[47]2021ANXA-1 k/o mice and 7 d DSS 2%-3%-5%Not mentionedAc2-26-nanoparticlesFluorescence imaging of MMPs, histology (as per Phillips et al[33]), whole transcriptome RNA sequencing and analysis3/7
Weber et al[48]20237 d DSS 2%84PrednisoloneBPR in situ, macroscopic (adhesions scoring), histology (as per Philips et al[33])3/7
Ntampakis et al[49]20237 d DSS 5%24AdMSC 5 × 106BPR ex situ, macroscopic (as per Bosmans et al[50]), HP, IL-6, TNF-a, VEGF7
Table 3 Malnutrition models of high-risk anastomosis
Ref.
Year
Colitis method
Sample size
Intervention
Test
Sampling day
McCauley et al[51]19913,5% agar diet for 7 d30BCAABody WT, BPR ex situ, tensile strength, protein content, HP-
Karahasanoglu et al[52]1998Low-protein diet for 10 d40Growth hormoneBody WT, BPR in situ, hydroxyproline4
Salman et al[53]200815 d72Cholerella sp. microalgaeBody WT, macroscopic (adhesions as per Ham et al[32]), BPR in situ, HP, histology (as per de Roy van Zuidewijn et al[54]), albumin, prealbumin, transferrin3/5/7/9/11/13/15
Gonçalves et al[55]200950% food restriction for 21 d80Pre-op nutritionTensile strength, histology5
Gündoğdu et al[56]201550% food restriction for 26 d18Pre-op nutritionBody WT, BPR in situ, HP4
Vizzotto Junior et al[57]2015Paired feeding160Omega-3Body WT, tensile strength, histology5
Danielski et al[58]201650% food restriction for 26 d45Vitamin CBody WT, macroscopic (as per Knightly et al[39]), histology, HP, MPO, TNF-a, nitrite/nitrate, oxidative damage7
Table 4 Obstruction models of high-risk anastomosis
Ref.
Year
Obstruction method
Sample size
Intervention
Test
Sampling day
Törnqvist et al[60]1990Silicone ring 6.5 mm54Diverting colostomyTensile strength, weight, HP2/7
Aguilar-Nascimento et al[61]1997Silk ligature108Nutritional solutions lavage of the colonMacroscopic, histology3/6
Erbil et al[62]2000Silk ligature144Nutritional solutions lavage of the colonBPR ex situ, HP, macroscopic3/6
Cağlikülekçi et al[63]2002Common bile duct ligation40rGHBPR ex situ, macroscopic, HP, macroscopic, histology (as per Greenhalgh et al[64])7
Lelyanov et al[65]2004Silk ligature60Sodium hypochlorite and ozone therapyBPR ex situ, survival, macroscopic, histology1/3/6/9/12
Krarup et al[59]2017Laparoscopic clip application32MMP inhibitionBody WT, HP, BPR in situ3
Table 5 Peritonitis models of high-risk anastomosis
Ref.
Year
Peritonitis method
Sample size
Intervention
Test
Sampling day
Vaneerdeweg et al[66]2000Gelatin capsule with faeces and barium sulphate40Gentamicin SpongesBPR in situ, mortality, weight loss4
Reijnen et al[67]2002Caecal ligation/perforation198Hyaluronan-based agentstPA activity1/3/7
Aydin et al[68]2006Caecal ligation/perforation24Laparostomy with Bogota bagBPR in situ, HP, adhesions (as per Zühlke et al[37])5
Li et al[69]2006Enterotomy360Fibrin glue and growth hormoneBPR in situ, HP, tensile strength, histology1/3/5
Buyne et al[70]2009Faecal inoculation148Recombinant tPABPR in situ, tensile strength, macroscopic, HP3/7
Kayaoglu et al[71]2009Caecal ligation/perforation80N-butyl-2-cyanoacrylateBPR ex situ, macroscopic (as per Knightly et al[39]), histology3/7
Pantelis et al[72]2010Caecal ligation/perforation or incomplete anastomosis206Collagen matrix coagulation factors I and IIa (Tachosil)BPR ex situ, histology (as per Biert et al[73], Verhofstad et al[74], Attard et al[75]), collagen type I-II, HP2/5/14
Rocha et al[76]2010Caecal ligation/perforation or incomplete anastomosis45Hyperbaric oxygen therapyTotal energy rupture test (tensile strength)4
Silva et al[77]2012Caecal ligation/perforation or incomplete anastomosis40BromoprideMacroscopic (Nair et al[78]), tensile strength (Versa test), histology, quantitative collagen analysis, HP3/7
Holmer et al[79]2014Faecal inoculation72Collagen fleece coatingBPR in situ, histology, collagen I, III, VEGF, MMP-131/3/7
Camargo et al[80]2013Faecal inoculation40Peritoneal lavage with bupivacaineTensile strength, survival5
Arikanoglu et al[81]2013Colon injury21Antibacterial sutureBPR in situ, HP, histology10
Donmez et al[82]2013Colon injury40Glutamine and GHBPR ex situ, HP5
Senol et al[83]2013E. Coli inoculation40Fibrin glueBPR ex situ, histology (as per Ehrlich-Hunt[25]), HP10
Silva et al[84]2014Caecal ligation/perforation80BromoprideMMP-1a, MMP-8, MMP-13, IL-1b, IL-6, IL-10, TNF-a, IFN-g3/7
Erginel et al[85]2014Caecal ligation/perforation40IP O3BPR ex situ, histology (as per Verhofstadt et al[74] and Philips et al[33]), HP7
Pommergaard et al[86]2014Incomplete anastomosis80Tachosil coatingTensile strength, clinical assessment7
Ercan et al[87]2015Caecal ligation/perforation40IP L-CarnitineBPR ex situ, histology (as per Ehrlich- Hunt[25]), HP5
Cakir et al[88]2015Incomplete anastomosis64SildenafilBPR ex situ, histology (as per Phillips et al[33]), HP, MDA, GSH3/7
Suárez-Grau et al[89]2016Incomplete anastomosis56Fibrinogen - thrombin collagen patchHistology (as per Biert scheme[73]), macroscopic (adhesions), survival15/30
Sozutek et al[90]2016Caecal ligation/perforation50PRPBPR in situ, Body WT, HP, histology (as per Verhofstadt et al[74])7
Ersoy et al[91]2016Caecal ligation/perforation60MelatoninBPR ex situ, HP, histology, IL-6, IL-10, INF-γ, CRP7
Çakır et al[92]2016Caecal ligation/perforation18IP O3BPR ex situ, TNF-a, IL-1β, MDA, MPO, histology22
Sukho et al[93]2018Incomplete anastomosis60AdMSCBPR in situ, macroscopic (as per Verco et al[94] and Zühlke et al[37]), histology3/7
Lorenzi et al[95]2017Caecal ligation/perforation40OmigananBPR in situ, histology (as per García et al[30]), HP7
Yıldırım et al[96]2021Caecal puncture21Growth factor collagen (FGF-C), abx collagen (AB-C)BPR ex situ, HP, macroscopic (as per Bosmans et al[50]), histology (as per Ehrlich et al[25])7
Nakamura et al[97]2021Incomplete anastomosis60HSMMBPR ex situ, macroscopic (as per Ham et al[32]), histology3/5/7/14/28
Aksu et al[98]2021Colon injury21Chlorhexidine gluconate and metronidazole-soaked spongesBPR in situ, hydroxyproline, histology10
Yilmaz et al[99]2021Caecal ligation/perforation32Polyurethane membraneBPR ex situ, HP, NOx, IL-6, TNF-a, tPA, macroscopic (as per Mazuji et al[100]), histology5
Table 6 Radiation models of high-risk anastomosis
Study
Year
Radiation dose
Sample size
Intervention
Test
Sampling day
Liu et al[101]200110 Gy74Lactobacillus plantarum 299vBody weight, WBC, mucosal MPO, HP, nucleotide, DNA and RNA content, colonic bacterial microflora, bacterial translocation, histology4/7/11
Kerem et al[102]2006500 cGy84Soluble FiberMacroscopic (adhesions as per van der Ham and Kort[32]), BPR in situ, HP, histology (as per de Roy van Zuidewijn et al[54]), MMP-2 activity3/7
Ozdemir et al[103]2013800 rad30AmifostineBPR ex situ, HP, histology5
Seker et al[104]2014485 cGy60PycnogenolBPR ex situ, HP, MDA, histology (as per Houdart et al[105])3/7
Simões Neto et al[106]2013660 cGy30Fraction electron beamBPR (not specified), histology7
Van de Putte et al[107]201727Gy48AdMSC18F-FDG-PET/CT, colonoscopy, histology32
Taşdöven et al[108]20196Gy48Ozon PRBPR in situ, histology (as per Houdart et al[105]), HP, MDA, MPO3/7
Yilmaz et al[109]202220Gy32Ozon PRBPR in situ, macroscopic (as per Knightly et al[39]), HP, MPO, histology (as per de Roy van Zuidewijn et al[54])5
Table 7 Ischaemia/reperfusion models of high-risk anastomosis
Ref.
Year
I/R method
Sample size
Intervention
Test
Sampling day
Terzi et al[110]2001SMA clampling 30 min65AllopurinolBPR in situ, macroscopic (adhesions as per Knightly et al[39]), histology (as per de Roy van Zuidewijn et al[54])3/7
Tireli et al[111]2003SMA clampling 30 min20PentoxifilineBPR ex situ, HP7
Miranda et al[112]2010SMA clamping 45 min45Methylene blueBPR ex situ, macroscopic, histology7
Celik et al[113]2013SMA clamping 45 min24ModelukastBPR ex situ, HP, MPO, MDA, caspase-3 activity, catalase, NOx, glutathione, SOD, TNF-a, IL-6, ALT, AST5
Akarsu et al[114]2017SMA clamping 10 min40SimvastatinBPR ex situ, HP8
Özkan et al[115]2018SMA clamping 30 min30MelatoninBPR ex situ, HP, histology (as per Nursal et al[116]), SOD, glutathione7
Özçay et al[117]2018SMA clamping 45 min40GHMacroscopic (as per Galili et al[118]), BPR ex situ, histology (as per Greenhalgh et al[64])7
Sayin et al[119]2020SMA clamping 45 min40IP montelukastBPR ex situ, macroscopic score (as per Knightly et al[39]), HP, histology (fibrosis)7
Eryilmaz et al[120]2020SMA clamping 45 min30Hydrogen rich salineBPR in situ, histology (as per Park et al[121] and Chiu et al[122]), TNF-a, IL-6, MDA, MPO5
Akıncı et al[123]2022SMA clamping 30 min36GenisteinBPR ex situ, HP, SOD, glutathione, histology (as per Piroglu et al[124])5
Table 8 Chemotherapy models of high-risk anastomosis
Ref.
Year
Chemo agent
Sample size
Intervention
Test
Sampling day
Nayci et al[125]2003IP 5-FU40Electromagnetic fieldTensile strength, HP7
Cetinkaya et al[126]2005IP mitomycin-C81GM-CSFBPR ex situ, HP, histology (as per Ehrlich et al[25])3
Kanellos et al[127]2006IP 5-FU and LEV60Fibrin glueBPR ex situ, HP, macroscopic (adhesions as per van der Ham and Kort[32]), histology (as per Phillips et al[33])8
Yildiz et al[128]20135-FU and 20 Gy60HBOTBPR ex situ, Weight, HP, histology (Fibrosis)5
Arapoglou et al[129]2017Irinotecan40IloprostBPR ex situ, macroscopic (as per van der Ham and Kort[32]), histology (as per Phillips et al[33]), HP8
Akyuz et al[130]20185-FU IV32MelatoninBPR ex situ, HP, histology, TNF-a, IL-1β7
Ocak et al[131]2019HIPEC with CIS30PRPBPR ex situ, HP, histology (as per Verhofstad et al[74])7
Gorur et al[132]2020IP 5-FU40PRPBody weight, BPR in situ, HP, histology (as per Verhofstad et al[74])7
Buk et al[133]2020IP OX30PRPBPR ex situ, histology (as per Verhofstad et al[74]), HP7
Table 9 Immunosuppression models of high-risk anastomosis
Ref.
Year
Immunosuppression method
Sample size
Intervention
Test
Sampling day
Dinc et al[134]2002Methylprednizolone80GM-CSFBPR ex situ, HP, histology (as per Ehrlich et al[25])3
Colak et al[135]2003Dexamethasone24TrapidilBPR ex situ, HP, histology (as per Ehrlich et al[25]), NOx, MDA7
Sakallioglu et al[136]2004Dexamethasone60eGFBPR ex situ, bursting site, HP, histology7
Inglin et al[137]2008MMF63IGF-IBPR ex situ, histology, Ki-672/4/6
Netta et al[138]2014Methylprednizolone50SCFABPR ex situ, CRP, IL-6, TNF-a4
Karakaya et al[139]2021Everolimus60AdMSCMacroscopic (as per Houston and Rotstein[140]), BPR ex situ, HP, histology4/7
Table 10 Macroscopic assessment of the anastomosis
Macroscopic assessment
Wound healing
van der Ham and Kort[32] scoreAdhesions
Zühlke et al[37] score for adhesions Adhesions
Mannheim index[42]Peritonitis presence and severity
Knightly et al[39] score for adhesionsAdhesions
Bosmans et al[50] score Anastomotic complication score
Nair et al[78] score Adhesions
Verco et al[94] score Abscess formation
Mazuji et al[100] score Adhesions
Galili et al[118] score Adhesions
Houston and Rotstein[140] score Adhesions
Table 11 Histologic assessment of the anastomosis
Ref.
Histologic assessment
Ehrlich et al[25]Erythrocytes, polymorphonucleated cells, mononuclear cells, fibroblasts, collagen fibers, fibrin
Houdart et al[105] and Hutschenreiter et al[144] as modified by García et al[30]Mucosal anastomotic re-epithelialization, neovascularization, fibroblasts, fibrosis, muscle layer destruction, neutrophil infiltration, lymphocyte infiltration, histiocyte infiltration, giant cell infiltration
Ehrlich et al[25] as modified by Phillips et al[33]Inflammatory cell infiltration, blood vessel in growth, fibroblast ingrowth, collagen deposition
Houdart et al[105]Granulocyte infiltration, mononuclear cell infiltration, fibroblastic proliferation, focal necrosis, exudate formation
Mucosal damage index by Mei et al[43]0: Normal mucosa, no damage on mucosal surface; 1: Mild hyperemia and edema, no erosion or ulcer on mucosal surface; 2: Moderate hyperemia and edema with erosion on mucosal surface; 3: Severe hyperemia and edema with necrosis and ulcer on mucosal surface, the major ulcerative area < 1 cm; 4: Severe hyperemia and edema with necrosis and ulcer on mucosal surface, the major ulcerative area > 1 cm
de Roy van Zuidewijn et al[54]Re-epithelialization, regeneration of muscularis propria, mucosal muscularis propria damage, necrosis, inflammatory exudate, granulation tissue, granulocytes, macrophages, fibroblasts, granulation tissue
Greenhalgh et al[64]Epithelization, cellular infiltration, fibroblastic proliferation, collagen deposition, neovascularization
Biert et al[73]Necrosis, polymorphonuclear cells, lymphocytes, macrophages, edema, epithelium, submucosal - muscular continuity, neovascularization, fibrosis
Attard et al[75]Mucosal continuity, muscular continuity, re-epithelialization, granulation tissue, polymorphonuclear cells, lymphocytes, macrophages, fibroblasts
Verhofstad et al[74]Necrosis, polymorphonuclear cells, lymphocytes, macrophages, edema, mucosal continuity, submucosal – muscular continuity
Nursal et al[116]Fibroblast infiltration, capillary formation, re-epithelialization, granulocyte infiltration, mononuclear cell infiltration
Park et al[121] and Chiu et al[122]Grade 1: Normal mucosa; grade 2: The subepithelial space at the tip of the villus; grade 3: Increase in subepithelial space; grade 4: Overlapping and spills of the floor of the villus; grade 5: Disintegration of the lamina propria; grade 6: Crypt layer injury; grade 7: Transmucosal infarction and grade 8: Transmural infarction
Piroglu et al[124]Inflammatory cell infiltration/concentration, neovascularization, fibroblastic activity, collagen fibers
Miltschitzky et al[15]Blood vessel ingrowth, fibroblasts, collagen formation, inflammatory cell infiltration, first layer in which continuity has been restored, number of healed layers, epithelium closed, crypt architecture restored, overall healing quality